{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:18:54Z","timestamp":1773836334730,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373414"],"award-info":[{"award-number":["82373414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300182"],"award-info":[{"award-number":["82300182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203442"],"award-info":[{"award-number":["82203442"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404067"],"award-info":[{"award-number":["82404067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.yexcr.2025.114791","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:32:59Z","timestamp":1760070779000},"page":"114791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1"],"prefix":"10.1016","volume":"453","author":[{"given":"Haixia","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huike","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2025.114791_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","article-title":"Biology of childhood acute lymphoblastic leukemia","volume":"62","author":"Bhojwani","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.yexcr.2025.114791_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091904","article-title":"[2] aberrant signaling pathways in T-Cell acute lymphoblastic leukemia","volume":"18","author":"Bongiovanni","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114791_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/gcc.22416","article-title":"Pediatric T-cell acute lymphoblastic leukemia","volume":"56","author":"Karrman","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.yexcr.2025.114791_bib4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/gcc.20684","article-title":"Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome","volume":"48","author":"Karrman","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.yexcr.2025.114791_bib5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3324\/haematol.13291","article-title":"Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3\/HOX11L2 gene expression on outcome","volume":"93","author":"Ballerini","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.yexcr.2025.114791_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0029-1239538","article-title":"Symptoms of childhood acute lymphoblastic leukemia: red flags to recognize leukemia in daily practice","volume":"221","author":"Bernbeck","year":"2009","journal-title":"Klin. P\u00e4diatr."},{"key":"10.1016\/j.yexcr.2025.114791_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ejh.12097","article-title":"Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol","volume":"90","author":"Toft","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.yexcr.2025.114791_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fonc.2014.00170","article-title":"New approaches to target T-ALL","volume":"4","author":"Roti","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2025.114791_bib9","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1021\/jm300915b","article-title":"Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions","volume":"55","author":"Hewings","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yexcr.2025.114791_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexcr.2025.114791_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nsmb0217-194c","article-title":"Erratum: BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"24","author":"Devaiah","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.yexcr.2025.114791_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.yexcr.2025.114791_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/13543776.2014.859244","article-title":"BET bromodomain inhibitors: a patent review","volume":"24","author":"Garnier","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.yexcr.2025.114791_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"[14] RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2025.114791_bib15","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexcr.2025.114791_bib16","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Ott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2025.114791_bib17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2025.114791_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107479","article-title":"Make your best BET: the emerging role of BET inhibitor treatment in malignant tumors","volume":"208","author":"Bechter","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yexcr.2025.114791_bib19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.yexcr.2025.114791_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2025.114791_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2247253","article-title":"BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3","volume":"28","author":"Ma","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.yexcr.2025.114791_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ajh.27385","article-title":"BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL","volume":"99","author":"Bauer","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.yexcr.2025.114791_bib23","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","article-title":"Targeted degradation of BET proteins in triple-negative breast cancer","volume":"77","author":"Bai","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114791_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neo.2019.01.003","article-title":"Characterizing the therapeutic potential of a potent BET degrader in merkel cell carcinoma","volume":"21","author":"Choi","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.yexcr.2025.114791_bib25","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-Lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2025.114791_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies","volume":"2","author":"Cordo","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.yexcr.2025.114791_bib27","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2025.114791_bib28","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2025.114791_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/carcin\/bgae006","article-title":"The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes","volume":"45","author":"Yu","year":"2024","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2025.114791_bib30","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double [30] [30] bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2025.114791_bib31","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1158\/0008-5472.CAN-21-0707","article-title":"BRD4 regulates transcription factor DeltaNp63alpha to drive a cancer stem cell phenotype in squamous cell carcinomas","volume":"81","author":"Fisher","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114791_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"[32] the hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2025.114791_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2025.114791_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia","volume":"46","author":"Knoechel","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.yexcr.2025.114791_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13578-022-00769-8","article-title":"BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma","volume":"12","author":"Chen","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.yexcr.2025.114791_bib36","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s11596-022-2625-1","article-title":"The roles and mechanisms of TRAT1 in the progression of non-small cell lung cancer","volume":"42","author":"Guo","year":"2022","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.yexcr.2025.114791_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/imm.13473","article-title":"Adoptive transfer of IL-4 reprogrammed Tc17 cells elicits anti-tumour immunity through functional plasticity","volume":"166","author":"Liu","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.yexcr.2025.114791_bib38","doi-asserted-by":"crossref","first-page":"20429","DOI":"10.1073\/pnas.0905139106","article-title":"Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival","volume":"106","author":"Bogunovic","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.yexcr.2025.114791_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246105","article-title":"Analysis of circulating immune subsets in primary colorectal cancer","volume":"14","author":"Lu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yexcr.2025.114791_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41598-020-80274-5","article-title":"A [40] novel immune prognostic index for stratification of high-risk patients with early breast cancer","volume":"11","author":"Lee","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2025.114791_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960866","article-title":"TRAT1 overexpression delays cancer progression and is associated with immune infiltration in lung adenocarcinoma","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272500391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272500391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:03:48Z","timestamp":1773824628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448272500391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S001448272500391X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114791","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114791"}}